EMA Authorised: Tarceva (erlotinib) — Cheplapharm Registration GmbH

View source ↗

Summary

Tarceva (erlotinib) has been authorised in the EU with Cheplapharm Registration GmbH as the marketing authorisation holder for non-small cell lung cancer and pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Pancreatic Neoplasms. MAH: Cheplapharm Registration GmbH. Decision date: 04/03/2025